Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | FDA grants priority review for Abbvie’s investigational therapy to treat (GT4) hep C virusBy: NAPSRx FDA priority review is usually granted to investigational therapies that treat a serious condition and would provide substantial improvement in safety or effectiveness, if approved. The treatment received priority review based on data published in The Lancet from the PEARL-I open-label, Phase 2b study . The study revealed 100 percent of GT4 patients without cirrhosis who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved SVR12 after receiving OBV/PTV/r and RBV for 12 weeks. "We are pleased that the FDA has granted priority review for our all-oral, interferon-free treatment for patients with chronic GT4 HCV infection," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "Submission of this NDA further underscores AbbVie's commitment to developing therapies to treat a wide range of patients living with chronic HCV infection." Hepatits C is characterized by inflammation of the liver caused by an infection with HCV and is transmitted when an infected person's blood enters the bloodstream of another person. Approximately, 3.2 million individuals are infected with HCV according to the CDC. (GT1) is the most prevalent form of HCV occurring in 73 percent of all cases, whereas genotype 4 accounts for 6 percent of HCV infections. CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES! With such industry leaders paving the way on identifying new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to promote their product both proficiently and efficiently. The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives( End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|